Using AI to improve cell therapies in solid tumors, Outpace clinches $144M

Outpace Bio is shooting to dose the first patient with its AI-designed cancer cell therapy in 2025, and it’s raised $144 million to reach that clinical milestone.

Thursday’s series B, led by RA Capital Management, brings the biotech’s total funding to $200 million. Outpace debuted in 2021 with a $30-million A round and a platform to overcome the challenges that have hampered the efficacy of cell therapies in treating solid tumours.